PAREA officially launched, with a Call to Action to EU policy makers
On 23 June 2022, the Psychedelic Access and Research European Alliance – PAREA, was officially launched at a virtual event: Preparing Europe for Novel Psychedelic-Assisted Therapies. Keynote Address was delivered by Dr Thomas Insel, former Director of the US National Institute of Mental Health (2002 – 2015). Other speakers included representatives from the European Parliament, European Commission, European Medicines Agency, patients and organizations representing them as well as PAREA members.
The launch event brought together multiple stakeholders to discuss the scientific advances in the area of psychedelic medicines, bridging the gap between patients and innovation and improving the regulatory context for studies on psychedelic-assisted treatments.
At the event, PAREA members launched a Call to Action to European decision-makers. It elaborated on the following recommendations:
Boost EU-funded research for psychedelic science
Foster competitive clinical trials and regulatory framework for psychedelic-assisted therapies
Create robust European psychotherapeutic standards to ensure optimal care and safety for patients
Foster evidence-based drug policies to catalyse psychedelic innovation in the areas of huge unmet needs
Develop European standards regarding training and infrastructure - before psychedelic treatments are approved - to build the patient access infrastructure that can meet the existing needs
PAREA is coming together to address those topics and provide evidence-based policy recommendations and expertise to the EU policymakers.
The meeting recording: